MARKET

CGEN

CGEN

Compugen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.97
-0.16
-1.22%
Opening 10:21 11/24 EST
OPEN
13.15
PREV CLOSE
13.13
HIGH
13.27
LOW
12.93
VOLUME
185.39K
TURNOVER
--
52 WEEK HIGH
19.90
52 WEEK LOW
5.20
MARKET CAP
1.07B
P/E (TTM)
-35.3293
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Compugen Q3 EPS $(0.09), Inline
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year.
Benzinga · 11/05 12:11
Compugen EPS in-line
Compugen (CGEN): Q3 GAAP EPS of -$0.09 in-line.Cash, related accounts and short-term and long-term bank deposits totaled ~$133M.Shares +4.7% PM.Press Release
Seekingalpha · 11/05 12:07
Compugen Q3 Earnings Preview
Compugen (NASDAQ:CGEN) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is -$0.09 (+10.0% Y/Y)Over the last 1 year, CGEN has beaten
Seekingalpha · 11/04 17:07
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
Zacks · 11/03 17:19
Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of new research data further supporting PVRIG as a potentially promising target for cancer immunotherapy. These data suggest that PVRIG inhibition may enhance T cell priming and infiltration into tumors and provide further evidence supporting the potential advantages of targeting PVRIG alone and in combination with TIGIT and PD-1 inhibitors, in tumors for which current checkpoint blockers have not proven successful. The new findings are delivered in a presentation at the 2020 TIGIT Therapies Digital Summit today, October 27, 2020, at 11:00 AM EDT.
PR Newswire · 10/27 12:00
Compugen To Present Research Data On PVRIG At 2020 TIGIT Therapies Digital Summit Today At 11:00 a.m. ET
HOLON, Israel, Oct. 27, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the
Benzinga · 10/27 11:16
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.
Zacks · 10/26 12:45
Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
PR Newswire · 10/22 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CGEN. Analyze the recent business situations of Compugen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CGEN stock price target is 20.38 with a high estimate of 28.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 43.48M
% Owned: 52.57%
Shares Outstanding: 82.69M
TypeInstitutionsShares
Increased
48
5.05M
New
42
1.22M
Decreased
19
2.22M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.48%
Pharmaceuticals & Medical Research
+0.15%
Key Executives
Chairman/Director
Paul Sekhri
President/Chief Executive Officer/Director
Anat Cohen-Dayag
Chief Financial Officer
Ari Krashin
Vice President
Zurit Levine
Vice President - Research & Development
John Hunter
Other
Henry Adewoye
Director
Jean-Pierre Bizzari
Director
Gilead Halevy
Director
Kinneret Livnat Savitsky
Director
Eran Perry
Director
Michal Preminger
Director
Sanford Zweifach
Independent Director
Yair Aharonowitz
Independent Director
Ruth Arnon
Independent Director
Arie Ovadia
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Compugen Ltd. (USA) stock information, including NASDAQ:CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.